secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2024-03-12T23:59:59+00:00
Accession:  0001104659-24-033247
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Q4 net loss narrows to $22.3M; cash runs only to mid-2024; FDA requires more TRANQUILITY data
--------------------------------------------------------------------------------

- Net loss $22.3M Q4 2023 vs $54.8M Q4 2022; full-year net loss $179.0M vs $165.8M.
- Cash and equivalents $65.2M at Dec 31, 2023, expected to fund operations only through mid-2024.
- FDA requires additional Phase 3 efficacy/safety data for BXCL501 in care facilities for Alzheimer's agitation (TRANQUILITY); at-home trial re-evaluated.
- SERENITY program: FDA meeting supports Phase 3 trial amendment for at-home use of 120 mcg BXCL501 for bipolar/schizophrenia agitation.
- Initiated formal process to assess strategic options for OnkosXcel Therapeutics subsidiary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465924033247/0001104659-24-033247-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465924033247/tm248359d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-033247

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer